CDK5R1 and neoplasm: Given other documented anti-tumor roles of CDK5 in other immune cell subsets and tumor-associated immune checkpoint molecule expression (22, 23, 46, 57–59), global targeting of CDK5/p35 in tumor-bearing hosts may represent a multi-pronged approach to novel immuno-oncology therapy.